Clinical Trials Logo

Lower Limb Ischemia clinical trials

View clinical trials related to Lower Limb Ischemia.

Filter by:

NCT ID: NCT02369809 Completed - Lower Limb Ischemia Clinical Trials

Non-Interventional Post Marketing Surveillance Study of Neovasculgen® in Patients With Chronic Lower Limb Ischemia

NVG-LIGHT
Start date: September 2012
Phase: Phase 4
Study type: Interventional

Aim of the study is to gain more knowledge about efficacy and safety of Neovasculgen® in daily clinical practice and obtain information about the quality of life in patients treated with Neovasculgen®.

NCT ID: NCT02304588 Recruiting - Diabetic Foot Clinical Trials

Stem Cell Therapy for Patients With Vascular Occlusive Diseases Such as Diabetic Foot

Start date: January 2013
Phase: Phase 1
Study type: Interventional

Mesenchymal stem cells with multidirectional differentiation potential,autologous stem cell transplantation into ischemic foot, make its differentiation to form new blood capillary, improve and restore the local blood flow.

NCT ID: NCT01937416 Recruiting - Diabetes Clinical Trials

Autologous Bone Marrow Mononuclear Cells Therapy in Diabetic Lower Limb Ischemia

Start date: January 2012
Phase: Phase 1
Study type: Interventional

This study is to evaluate the safety and efficacy of autologous bone marrow mononuclear cells transplantation in diabetic patients with lower limb ischemia.

NCT ID: NCT01305863 Active, not recruiting - Lower Limb Ischemia Clinical Trials

Feasibility Study of the TGI Adipose-derived Stromal Cell (ASC)-Coated ePTFE Vascular Graft

TGI-PVG-IDE
Start date: February 2011
Phase: N/A
Study type: Interventional

Researchers are actively seeking a way to coat the inside of a synthetic graft so that it more closely resembles native vessels and therefore has low thrombogenicity and low incidence of stenosis. Using a biological coating comprised of autologous stromal cells derived from the patient's own adipose tissue is a logical solution. Considerable experimental evidence exists that such a coating is relatively non-thrombogenic and improves long-term graft patency. The Company's TGI Cell Isolation System (CIS) for isolating and concentrating adipose-derived stromal cells (ASC) can be used to fill the pressing medical need for small-diameter synthetic vascular grafts. The TGI CIS enables the user to prepare a stem cell-based biological coating from adipose tissue liposuctioned from the patient. The cells derived from the adipose tissue are then sodded onto the internal lumen of the vascular graft to improve long term patency.